Maxygen, Chr. Hansen Holding A/S deal

MAXY and CHRH's ALK-Abello A/S subsidiary will develop recombinant allergy therapeutics. The three-year deal will combine MAXY's MolecularBreeding directed evolution technology with ALK-Abello's alle...